Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity
dc.contributor.author | Hong, Gloria J. | |
dc.contributor.author | Stinnett, Sandra S. | |
dc.contributor.author | Freedman, Sharon F. | |
dc.contributor.author | Wallace, David K. | |
dc.contributor.author | Prakalapakorn, S. Grace | |
dc.contributor.department | Ophthalmology, School of Medicine | en_US |
dc.date.accessioned | 2021-10-14T16:58:32Z | |
dc.date.available | 2021-10-14T16:58:32Z | |
dc.date.issued | 2021-05-06 | |
dc.description.abstract | Guidelines on managing infants after initial anti-vascular endothelial growth factor (VEGF) treatment (eg, bevacizumab) for retinopathy of prematurity (ROP) are limited. We found that following initial bevacizumab treatment for ROP, prophylactically lasering infant eyes before hospital discharge reduced the number and duration of outpatient ROP screening examinations compared with following infants, per current United States (US) ROP screening guidelines. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Hong, G. J., Stinnett, S. S., Freedman, S. F., Wallace, D. K., & Prakalapakorn, S. G. (2021). Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity. Journal of American Association for Pediatric Ophthalmology and Strabismus. https://doi.org/10.1016/j.jaapos.2021.02.002 | en_US |
dc.identifier.issn | 1091-8531 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/26779 | |
dc.language.iso | en | en_US |
dc.publisher | Science Direct | en_US |
dc.relation.isversionof | 10.1016/j.jaapos.2021.02.002 | en_US |
dc.relation.journal | Journal of American Association for Pediatric Ophthalmology and Strabismus | en_US |
dc.rights | IUPUI Open Access Policy | en_US |
dc.source | Author | en_US |
dc.subject | Prophylactic laser | en_US |
dc.subject | bevacizumab treatment | en_US |
dc.subject | retinopathy of prematurity | en_US |
dc.title | Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity | en_US |
dc.type | Article | en_US |